TP53 and acute myeloid leukemia: To test this hypothesis, we conducted proliferation competition assays in a panel of 7 human AML cell lines: 4 in which p53 activity is abrogated by TP53 inactivating mutations (THP-1, SET-2, HEL, U-937), and 3 in which TP53 is wild-type (MOLM-13, OCI-AML3, MV4-11).